07:42 AM EDT, 09/18/2024 (MT Newswires) -- Purple Biotech ( PPBT ) said Wednesday interim data from its phase 2 study evaluating CM24 in combination with Bristol Myers Squibb's ( BMY ) nivolumab plus chemotherapy in patients with pancreatic cancer compared to chemotherapy alone 'improved overall survival' of pancreatic ductal adenocarcinoma patients.

The patients' overall survival showed a 90% reduction in risk of death and prolongation of 4.1 months in median overall survival.

The randomized study enrolls 63 patients across 18 centers in the US, Spain, and Israel, and topline results are expected in Q4, the company said.

Purple Biotech's ( PPBT ) shares rose more than 5% in recent Wednesday premarket activity.

Price: 7.40, Change: +0.38, Percent Change: +5.41